Revision as of 11:35, 9 February 2006 edit24.72.227.41 (talk)No edit summary← Previous edit | Revision as of 20:18, 11 February 2006 edit undoTsalman (talk | contribs)77 editsNo edit summaryNext edit → | ||
Line 13: | Line 13: | ||
Selective beta blockers generally only block the type 1 receptor. They gradually become less selective at higher doses. Examples of selective beta<sub>1</sub> blockers in common use include ] and ]. | Selective beta blockers generally only block the type 1 receptor. They gradually become less selective at higher doses. Examples of selective beta<sub>1</sub> blockers in common use include ] and ]. | ||
Since they lower heart rate, beta blockers have been used by some ] ] to provide more aiming time between ]s. Some ] use beta blockers to avoid ] and tremor during ]s and ]s. Beta blockers decrease nocturnal ] release. | Since they lower heart rate, beta blockers have been used by some ] ] to provide more aiming time between ]s. Some ] use beta blockers to avoid ] and tremor during ]s and ]s. Beta blockers decrease nocturnal | ||
] release. | |||
===Beta Blockers at a Glance=== | |||
* Beta 1 selective (Cardio selective)— Atenolol, Acebutolol, Betaxolol, Bisoprolol, Esmolol, Metoprolol, Nebivolol. | |||
# Preferable in pts. with Bronchospastic disease, Diabetes, Peripheral vascular ds. e.g. Raynaud’s phenomenon (bronchoconstriction, inhibition of glycogenolysis, vasoconstriction are due to b2 blockade) | |||
* Beta 2 selective—Butoxamine | |||
* Additional a1 antagonistic activity—Bucindolol, Carvedilol, Labetolol, Medroxolol | |||
# Potentially advantageous in pts. with hypertension, occlusive peripheral artery ds. (Promote vasodilatation) | |||
* Partial agonist (intrinsic sympathomimetic) activity—Acebutolol, Bopindolol, Carteolol, Celiprolol*, Labetolol, Oxiprenolol, Penbutolol, Pindolol. | |||
(* Beta 1 selective antagonist with b2-agonist activity; also has non-adrenergic receptor- mediated vasodilating property.) | |||
# Potentially advantageous in pts. with hypertension, occlusive peripheral artery ds. (Promote vasodilatation) | |||
# Less likely to cause Bradycardia, Bronchoconstriction, Lipid abnormalities. | |||
Local anaesthetic action (Membrane stabilizing property/ Na+ channel blockade)— Acebutolol, Propranolol, Propafenone. | |||
Slight activity—Betaxolol, Labetolol, Metoprolol, Pindolol | |||
Lipid solubility: High —Propranolol, Penbutolol | |||
# Readily cross BBB—central effects, large vol. of distribution | |||
Low –Atenolol, Esmolol, Nadolol | |||
# Don’t cross BBB—no central effects | |||
Half-life: Long t½---Betaxolol, Nadolol (14- 22 hrs.) # OD dosing. | |||
Shortest --Esmolol (8- 10 mins. —Hydrolyzed by esterases in erythrocytes) | |||
# Given as i.v. infusion in urgent settings. | |||
Others —-between 3- 12 hrs. | |||
Oral bioavailability: | |||
*High --Betaxolol, Pindolol, Penbutolol, and Sotalol | |||
*Low –Carvedilol, Esmolol, Labetolol, Nadolol, Propranolol | |||
*No effect on plasma rennin activity—Pindolol | |||
*Anti-oxidant activity—Carvedilol | |||
*Antiarrythmic action (independent of b blocking action) – Sotalol | |||
=USES= | |||
* Hypertension | |||
* Prophylaxis of Angina | |||
* Prophylaxis of MI—Metoprolol, Propranolol, Timolol | |||
* Mild- Moderate CHF (Contraindicated in compensated Ht. failure) – Bisoprolol, Bucindolol, Carvedilol, Metoprolol | |||
* Hypertrophic obstructive cardiomyopathy – esp. Propranolol | |||
* Pheochromocytoma (a blocker given before b blocker) | |||
* Ac. Dissecting aortic aneurysm | |||
* Marfan’s syndrome (Chr. Tt. with Propran. slows progression of aortic dilatation & its complications) | |||
* Hyperthyroidism | |||
* Prophylaxis of Migraine -- Metoprolol, Propranolol, Timolol | |||
* Somatic manifestations of anxiety (e.g. tremors)-- Propranolol | |||
* Glaucoma (↓ Aqueous production) –Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol | |||
* Prevention of vericial bleeding in portal hypertension -Propranolol, Nadolol | |||
--Dr M Tariq Salman 20:18, 11 February 2006 (UTC) | |||
==External links== | ==External links== |
Revision as of 20:18, 11 February 2006
Beta blockers or beta-adrenergic blocking agents are a class of drugs used to treat a variety of cardiovascular conditions and some other diseases.
Beta blockers block the action of epinephrine and norepinephrine on the β-adrenergic receptors in the body (primarily in the heart, peripheral blood vessels, bronchi, pancreas, and liver). The hormones and neurotransmitters stimulate the sympathetic nervous system by acting on these receptors.
There are three types of beta receptors: β1-receptors located mainly in the heart, and β2-receptors located all over the body, but mainly in the lungs, muscles and arterioles. β3-receptors are less well characterised, but have a role in fat metabolism.
Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease and hypertension. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.
Drugs that block β2 receptors generally have a calming effect and are prescribed for anxiety, migraine, esophageal varices and alcohol withdrawal syndrome, among others.
Many beta blockers affect both type 1 and type 2 receptors; these are termed non-selective blockers. Propranolol and nadolol are examples. Selective beta blockers primarily affect β1-receptors. Non-selective beta blockers should generally not be used in patients with asthma or any reactive airway disease. Doing so can precipitate bronchospasm by blocking the β2 mediated relaxation of the bronchiole muscles.
Selective beta blockers generally only block the type 1 receptor. They gradually become less selective at higher doses. Examples of selective beta1 blockers in common use include atenolol and metoprolol.
Since they lower heart rate, beta blockers have been used by some Olympic marksmen to provide more aiming time between heart beats. Some musicians use beta blockers to avoid stage fright and tremor during auditions and performances. Beta blockers decrease nocturnal melatonin release.
Beta Blockers at a Glance
- Beta 1 selective (Cardio selective)— Atenolol, Acebutolol, Betaxolol, Bisoprolol, Esmolol, Metoprolol, Nebivolol.
- Preferable in pts. with Bronchospastic disease, Diabetes, Peripheral vascular ds. e.g. Raynaud’s phenomenon (bronchoconstriction, inhibition of glycogenolysis, vasoconstriction are due to b2 blockade)
- Beta 2 selective—Butoxamine
- Additional a1 antagonistic activity—Bucindolol, Carvedilol, Labetolol, Medroxolol
# Potentially advantageous in pts. with hypertension, occlusive peripheral artery ds. (Promote vasodilatation)
- Partial agonist (intrinsic sympathomimetic) activity—Acebutolol, Bopindolol, Carteolol, Celiprolol*, Labetolol, Oxiprenolol, Penbutolol, Pindolol.
(* Beta 1 selective antagonist with b2-agonist activity; also has non-adrenergic receptor- mediated vasodilating property.)
- Potentially advantageous in pts. with hypertension, occlusive peripheral artery ds. (Promote vasodilatation)
- Less likely to cause Bradycardia, Bronchoconstriction, Lipid abnormalities.
Local anaesthetic action (Membrane stabilizing property/ Na+ channel blockade)— Acebutolol, Propranolol, Propafenone. Slight activity—Betaxolol, Labetolol, Metoprolol, Pindolol Lipid solubility: High —Propranolol, Penbutolol
# Readily cross BBB—central effects, large vol. of distribution
Low –Atenolol, Esmolol, Nadolol
# Don’t cross BBB—no central effects
Half-life: Long t½---Betaxolol, Nadolol (14- 22 hrs.) # OD dosing.
Shortest --Esmolol (8- 10 mins. —Hydrolyzed by esterases in erythrocytes) # Given as i.v. infusion in urgent settings. Others —-between 3- 12 hrs.
Oral bioavailability:
*High --Betaxolol, Pindolol, Penbutolol, and Sotalol *Low –Carvedilol, Esmolol, Labetolol, Nadolol, Propranolol
- No effect on plasma rennin activity—Pindolol
- Anti-oxidant activity—Carvedilol
- Antiarrythmic action (independent of b blocking action) – Sotalol
USES
- Hypertension
- Prophylaxis of Angina
- Prophylaxis of MI—Metoprolol, Propranolol, Timolol
- Mild- Moderate CHF (Contraindicated in compensated Ht. failure) – Bisoprolol, Bucindolol, Carvedilol, Metoprolol
- Hypertrophic obstructive cardiomyopathy – esp. Propranolol
- Pheochromocytoma (a blocker given before b blocker)
- Ac. Dissecting aortic aneurysm
- Marfan’s syndrome (Chr. Tt. with Propran. slows progression of aortic dilatation & its complications)
- Hyperthyroidism
- Prophylaxis of Migraine -- Metoprolol, Propranolol, Timolol
- Somatic manifestations of anxiety (e.g. tremors)-- Propranolol
- Glaucoma (↓ Aqueous production) –Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol
- Prevention of vericial bleeding in portal hypertension -Propranolol, Nadolol
--Dr M Tariq Salman 20:18, 11 February 2006 (UTC)
External links
- Musicians using beta blockers
- Better Playing Through Chemistry by Blair Tindall, New York Times, October 17, 2004. (Discussing the use of beta-blockers among professional musicians.)
Beta blockers (C07) | |
---|---|
β, non-selective | |
β1-selective | |
β2-selective | |
α1- + β-selective | |
|